Plasma fibrinogen levels are correlated with postoperative distant metastasis and prognosis in esophageal squamous cell carcinoma.
This study investigated the correlation of preoperative plasma fibrinogen level with distant metastasis and prognosis in esophageal squamous cell carcinoma (ESCC). A total of 255 patients with ESCC who underwent surgery in Zhejiang cancer hospital (Hangzhou, China), between October 2006 and December 2009, were evaluated in this retrospective study. Population controls were selected from a pool of cancer-free subjects in the same region. Each patient and cancer-free people provided 3-mL pretreatment blood. Plasma fibrinogen level was measured by the Clauss method. The effects of hyperfibrinogenemia on locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS), relapse-free survival (RFS), and overall survival (OS) were assessed using Kaplan-Meier analysis. Independent prognostic factors were identified in the multivariate Cox analysis. The proportion of hyperfibrinogenemia was higher in ESCC patients than those in controls (40.4% vs 13.6%). Subjects with hyperfibrinogenemia had a significantly higher risk of ESCC than those with normal plasma fibrinogen level (adjust OR = 4.61; 95% CI = 3.02-7.01, P < 0.001) after adjusted for age, sex and smoking status. The Kaplan-Meier curves showed that patients with hyperfibrinogenemia had worse DMFS, RFS and OS (P < 0.001). Tumor length, lymph node metastasis and plasma fibrinogen level were independent prognostic factors of ESCC (P < 0.05). Increased plasma fibrinogen level was significantly associated with elevated risk of ESCC. Preoperative plasma fibrinogen level was a predictor of distant metastasis and independently associated with prognosis of patients with ESCC.
Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.|Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang, China.
Danhong
D
Zhang
Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.|Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang, China.
Xia
X
Zhou
Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.|Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang, China.
Wuan
W
Bao
Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.|Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang, China.
Ying
Y
Chen
Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.|Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang, China.
Lei
L
Cheng
Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.|Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang, China.
Guoqin
G
Qiu
Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.|Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang, China.
Liming
L
Sheng
Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.|Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang, China.
Yongling
Y
Ji
Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.|Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang, China.
Xianghui
X
Du
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D016009:Chi-Square Distribution; D002681:China; D018450:Disease Progression; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D000077277:Esophageal Squamous Cell Carcinoma; D016629:Esophagectomy; D005260:Female; D005340:Fibrinogen / Q000032:analysis*; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D005340:Fibrinogen
esophageal squamous cell carcinoma; fibrinogen; metastasis; prognosis